Pfizer - together with COVID-jab partner BioNTech - was a major sponsor of Sunday's Oscars award ceremony, a broadcast that unexpectedly shone an un-missable spotlight on the hair-loss disease alopecia.
In one heck of a coincidence, Pfizer just happens to be in a race for market dominance of its soon-to-be-released cure for - you guessed it - alopecia.
Pfizer's alopecia therapy has been linked to a reduction in hair loss in early topline clinical data, setting the stage for a scrap with Eli Lilly and Incyte in the title fight for a potential blockbuster opportunity.
Ritlecitinib has met its primary endpoint in a phase 2b/3 clinical trial of patients with alopecia areata, Pfizer reported Wednesday.
Pfizer's ritlecitinib joined Lilly and Incyte's Olumiant on the list of drugs to hit the primary endpoint in pivotal alopecia trials on Wednesday-and Concert Pharmaceuticals is following closely behind.
Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator currently in development for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn's Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata.
Now, today comes the revelation that Pfizer, which will soon be competing to sell the most therapeutics for alopecia sufferers, was a major sponsor of the Oscars.
Wednesday, March 30, 2022
Look Who Has a Drug for Alopecia in Development
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment